Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis
- First Online:
- Cite this article as:
- Mori, M., Murata, Y., Matsuo, A. et al. Neurol Ther (2014) 3: 67. doi:10.1007/s40120-013-0015-0
A large-scale clinical trial, the Sequence Trial Alternatives to Relieve Depression (STAR*D) study, concluded that about one-third of the studied patients with major depressive disorder remitted during the initial treatment with selective serotonin reuptake inhibitors and that approximately half of the remitted subjects relapsed over a 1-year follow-up. The development of new therapeutic approaches with potent efficacy and good tolerability for the treatment of depressive disorders is of great importance. Adult hippocampal neurogenesis has been proposed to be important for understanding and treating depression and anxiety. The present study aimed to elucidate whether or not 5-hydroxytryptamine 1A (5-HT1A) receptor partial agonists have a potential therapeutic effect for the treatment of depressive and anxiety disorders, from the standpoint of neurogenesis.
Male Sprague–Dawley rats were subcutaneously administered a vehicle or tandospirone (TDS) (1 or 10 mg/kg) once daily for 14 days. The effects of chronic TDS treatment on neurogenesis were evaluated on the day after the last injection. The quantification of hippocampal neurogenesis was estimated using immunostaining with doublecortin (DCX), a marker protein of newborn neurons.
Chronic TDS treatment resulted in a significant increase in the number of DCX-positive cells per volume of dentate gyrus in a dose-dependent manner.
The results strongly suggest that 5-HT1A receptor partial agonists would be useful and beneficial in the treatment of depressive and anxiety disorders through increased hippocampal neurogenesis.
Keywords5-HT1A receptor partial agonist Chronic treatment Clinical efficacy Depression and anxiety Dose dependent Doublecortin Hippocampal neurogenesis Novelty suppressed feeding Tandospirone
Depression and anxiety are common public health problems, affecting 5–10% of the world’s population at any given time, and they share a high degree of comorbidity (up to 80–90%) . Although there are a number of medications available for the treatment of depressive and anxiety disorders, a considerable number of patients cannot achieve remission . The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, a large-scale clinical trial for major depressive disorder (MDD), demonstrated that only about one-third of the participants remitted during the initial treatment with citalopram and that approximately half of the remitted participants relapsed over a 1-year follow-up [3, 4, 5]. Baldwin et al. , in a review of previous studies of pharmacotherapies for generalized anxiety disorder (GAD), concluded that the remission rate is less than 60% for GAD patients treated with selective serotonin reuptake inhibitors (SSRIs). Therefore, the development of effective new therapeutic approaches with good tolerability for the treatment of depressive and anxiety disorders is of great importance.
Adult hippocampal neurogenesis has been proposed as important for understanding and treating depression and anxiety . The hippocampus is not only involved in cognitive functions, but also is a key structure for regulating affective and anxiety states. The subgranular zone (SGZ) in the dentate gyrus (DG) of the hippocampus is one of only a few brain regions where the production of new neurons occurs throughout the lifetime of animals, including humans [8, 9]. Accumulating evidence shows that adult hippocampal neurogenesis is decreased by stress and increased by chronic administration of antidepressants, such as fluoxetine [10, 11]. Thus, changes in adult hippocampal neurogenesis may be related to the pathophysiology of depressive and anxiety disorders and to the beneficial effects of antidepressant treatment [7, 9, 12, 13].
The azapirone drugs, including buspirone, tandospirone (TDS), and gepirone which act as 5-hydroxytryptamine 1A (5-HT1A) receptor partial agonists, have been widely used in the treatment of anxiety disorder [14, 15]. In practice, benzodiazepines are most frequently used in combination with standard antidepressants for the initial treatment and maintenance therapy for depressive disorders when comorbid anxiety exists . We and many other researchers have shown that benzodiazepines produce drug dependence, sedation, and cognitive impairment in humans and rodents [17, 18, 19, 20]. In contrast, azapirone-type 5-HT1A receptor agonists have the advantage of producing significantly fewer adverse effects than benzodiazepines and result in little dependence [21, 22, 23]. Recently, two animal studies revealed that co-administering benzodiazepines with antidepressants prevents an SSRI-induced increase in hippocampal neurogenesis, which suggests that the use of benzodiazepines delays the therapeutic onset and reduces the clinical efficacy of SSRIs [24, 25]. In contrast to above reports concerning benzodiazepines, 5-HT1A receptor agonists are considered to have an augmenting effect on clinical efficacy for depressive disorders when administered in combination with an SSRI. Recently, several authors have reported that augmentation therapy consisting of a combination of antidepressants with 5-HT1A receptor agonist treatment is a better therapeutic strategy for MDD than antidepressant monotherapy [3, 26, 27].
In our previous pilot study, we showed that TDS, the only azapirone drug available in Japan, has excellent clinical efficacy for the treatment of GAD and mixed anxiety–depression and that it has no significant adverse effects . We also showed that TDS had a remarkable anxiolytic effect in an animal model of anxiety and that the potency of the pharmacological effect was increased dose dependently, without a sedative effect .
In addition, we conducted a preliminary clinical study about the efficacy of augmentation therapy consisting of a combination of paroxetine and TDS (Sakamoto et al., unpublished data). In that study, among a consecutive series of 37 patients with MDD who were treated with the combination of paroxetine and TDS, 29 subjects (78.4%) achieved remission at 12 weeks after the start of treatment. Furthermore, our 4-year follow-up study found recurrence in only 5 (17.9%) of 28 patients who had remitted.
Thus, 5-HT1A receptor partial agonists, clinically available and safe drugs, may have great usefulness in the treatment of psychiatric illness, such as depression and anxiety.
It is well known that 5-HT1A receptors play an important role in the regulation of mood, anxiety, and cognition . 5-HT1A receptors also have been shown to regulate hippocampal neurogenesis in the SGZ of the DG. Santarelli et al.  showed that 5-HT1A receptor-deficient mice did not respond to chronic fluoxetine treatment, as measured by the change in neurogenesis. Reporting on the effect of 5-HT1A receptor agonists on neurogenesis, Banasr et al.  and Soumier et al.  showed increased granule cell genesis in the DG during treatment with 8-hydroxy-2-dipropylaminotetralin hydrobromide (8-OH-DPAT), a 5-HT1A receptor full agonist. However, 8-OH-DPAT is a chemical reagent that is not available for clinical use. Of interest, Radley and Jacobs  reported that the acute administration of 5-HT1A receptor full antagonist WAY100635 decreased neurogenesis in the DG.
Based on previous reports by many authors and our studies described above, we hypothesize that hippocampal neurogenesis plays an important role in the clinical efficacy of 5-HT1A receptor partial agonists.
This study aimed to elucidate the potential therapeutic effect of 5-HT1A receptor partial agonists in the treatment of depressive and anxiety disorders, from the standpoint of neurogenesis.
Male Sprague–Dawley rats (Kyudo Co., LTD., Tosu, Japan) weighing 150–200 g upon arrival were studied. They were housed individually in a temperature (23 ± 2 °C), humidity (60 ± 10%), and light-controlled room (reverse 12-h light/dark cycle, lights off at 7:00 a.m.). Food and water were available ad libitum. All animal care and use procedures were performed in compliance with the regulations established by the Experimental Animal Care and Use Committee of Fukuoka University, which are in accordance with the universal principles of laboratory animal care.
Tandospirone citrate was supplied by Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). The drug was dissolved in saline and prepared at a concentration of 1 or 10 mg/mL, then injected subcutaneously in a volume of 1 mL/kg. The control animals were given the same volume of vehicle solution. The dosage of TDS was chosen on the basis of previous reports [23, 33]. One week following the arrival of the animals at the laboratory, they were injected with either the vehicle or TDS (1 or 10 mg/kg) once daily for 14 days.
Novelty Suppressed Feeding (NSF) test
Novelty Suppressed Feeding test was performed as previously described [34, 35, 36]. Briefly, animals were fasted for 24 h, then placed in a corner of a large polypropylene tub (50 × 40 × 20 cm) with a food pellet positioned in the center. The time to the first chewing of the food (latency) was recorded. The test was continued for 12 min and if the animal had not eaten the result was scored as 12 min. To evaluate the acute effect of TDS, the rats were initially injected with the vehicle or TDS, then 20 min later subjected to the first NSF test. In the experiment investigating the chronic effect of TDS, drug treatment was done for 14 days, and the next day the rats were subjected to the second NSF test.
Brain Slice Preparation
Two hours after termination of the second NSF test, the rats were deeply anesthetized with sodium pentobarbital and perfused transcardially with saline (1,000 mL/kg) followed by 250 mL of 4% ice-cold paraformaldehyde in 0.1 M phosphate buffered saline (PBS; pH 7.4). The brain was removed from the skull and post-fixed overnight in the same fixative at 4 °C, then placed into graded concentrations of sucrose in PBS at 4 °C. Coronal sections of the brain were cut (30 μm sections) through the entire hippocampus (bregma −1.72 to −6.84 mm ) on a freezing microtome. Sections were mounted onto silane-coated glass slides, then dried and stored at −80 °C prior to processing.
After washing in PBS, sections were incubated for 30 min in 3% H2O2 to eliminate endogenous peroxidases. After blocking with 5% normal goat serum, the sections were incubated with anti-doublecortin (DCX) primary antibody (rabbit, 1:1,000; Abcam, Cambridge, UK) overnight at 4 °C. They were then incubated for 2 h with secondary antibody (biotinylated goat anti-rabbit, 1:200; Vector Laboratories, Burlingame, CA, USA) followed by amplification with an avidin–biotin complex (1:300; DAKO Japan, Kyoto, Japan), and the cells were visualized with diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA). The sections were air-dried and counterstained with hematoxylin, then dehydrated, cleared in xylene, and coverslipped.
Stereological Analysis of DCX-Positive Cells in DG
The total number of DCX-positive cells was counted throughout the rostrocaudal extent of the DG of granule cell layer (GCL) using a 40× objective (Nikon E600, Nikon, Tokyo, Japan). The optical fractionator method was used for counting, as previously described with minor modifications . Briefly, in every section, the contour of the GCL/SGZ was first delineated for counting using the tracing function of the StereoInvestigator (MicroBrightField Japan, Chiba, Japan) software. Following this, the optical fractionator component was activated by entering parameters such as the grid size, the thickness of the guard zone, and the optical dissector height. A computer-driven motorized stage then randomly determined the counting frame locations. The StereoInvestigator software used the optical fractionator formula to calculate the total number of DCX-positive cells per DG. Every eighth section throughout the DG was analyzed, yielding a mean of 20 sections per brain. The total number of DCX-labeled cells in the GCL together with the SGZ, which is defined as a two-cell-body-wide zone along the border of the GCL, was estimated. This procedure ensured a systematic random sample of the sections, in which all parts of the DG region analyzed had the same opportunity of being represented. The precision of estimates of the number of cells was expressed using the coefficient of error (CE). The stereological sampling scheme was considered adequate when CE was less than 0.10 .
One-way factorial analysis of variance (ANOVA) was performed to test for differences in latency in the NSF test and for quantification of DCX-positive cells, followed by Bonferroni/Dunn post hoc analysis for further examination of group differences. For the NSF test, the Kaplan–Meier method with Mantel–Cox log-rank test was used to determine differences in survival curves where the latency to eat was the limit of survival as previously described . All data are represented as mean ± standard error of the mean (SEM). P value of <0.05 was adopted for significance.
The Effects of Tandospirone in the NSF test
The Effects of Tandospirone on DCX-Positive Cells in the Dentate Gyrus of the Hippocampus
In the present study, administration of TDS for 14 days increased the number of DCX-positive cells in the DG of adult rat hippocampus in a dose-dependent manner. This result suggests that chronic treatment with TDS increases hippocampal neurogenesis in humans, because DCX can be used as a quantitative marker of new nerve cells in the adult brain [39, 40]. Adult hippocampal neurogenesis has been shown to be important for understanding and treating depression and anxiety . Based on our result, we propose that 5-HT1A receptor partial agonists would be of great clinical usefulness for the treatment of depressive and anxiety disorders because of increased hippocampal neurogenesis. However, it will also be necessary in future studies to use other markers, such as Ki-67, NeuroD or NeuN, at each stage of neurogenesis and to assess the maturation index and synaptic branching in the hippocampal neurons to establish the relationship between 5-HT1A activation and the neurogenic effect on anxiolytic and antidepressant response.
To our knowledge, this is the first report to show chronic, positive effects of a 5-HT1A receptor partial agonist, a clinically available and safe drug, on hippocampal neurogenesis in rodents. Several studies have reported hippocampal neurogenesis using 5-HT1A receptor agonists or antagonists that are experimental reagents not available for clinical use. Banasr et al.  and Soumier et al.  found an increasing effect of 8-OH-DPAT, a 5-HT1A receptor full agonist, on granule cell genesis in the DG of the hippocampus of rodents, and Radley and Jacobs  reported that the acute administration of 5-HT1A receptor full antagonist WAY100635 decreases neurogenesis in the DG of the hippocampus of rodents. Further study will be necessary to determine if the administration of 5-HT1A receptor antagonists, such as WAY100635, block the increase in neurogenesis induced by chronic TDS administration.
The anxiolytic effect of 5-HT1A receptor partial agonists has been established and it has been shown that 5-HT1A receptor partial agonists have no remarkable adverse effects and little dependency. Furthermore, previous clinical trials suggest the possibility of 5-HT1A receptor partial agonists as useful drugs for the treatment of schizophrenia, eating disorders, Parkinson’s disease, and cognitive dysfunction [41, 42, 43, 44, 45, 46]. Recently, hippocampal neurogenesis has been associated with the etiology and treatment of neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease . Also, Barbarich-Marsteller et al.  reported that hippocampal cell proliferation in the DG was reduced in an animal model of anorexia nervosa. Our results suggest the clinical usefulness of 5-HT1A receptor partial agonists for the treatment of such important diseases as those described above.
5-HT1A receptor partial agonists can also be used as augmentation therapy in conjunction with antidepressants for the treatment of depressive disorder . Recent animal studies indicate that co-administering benzodiazepines with antidepressants prevents the SSRI-induced increase in hippocampal neurogenesis, although benzodiazepines are often used as anxiolytics in combination with antidepressants for depressive disorders, especially in the early phases of therapy when comorbid anxiety is present [16, 24, 25]. In contrast, our result suggesting that TDS treatment induces an increase in hippocampal neurogenesis helps explain the augmenting effect of 5-HT1A receptor partial agonists on their clinical efficacy for depressive disorders when administered in combination with an SSRI.
In the present study, acute treatment with TDS significantly decreased the latency to feeding in the NSF test. The NSF test assesses anxiety behavior by measuring the time it takes an animal to approach and eat a familiar food in an aversive environment. Also, the NSF test is considered to be very sensitive to chronic treatment with antidepressants, including SSRIs . Although it is difficult to prove that acute treatment with TDS exerts the same anxiolytic effect as chronic antidepressant treatment, this result suggests that TDS has specific efficacy for anxiety disorders. We also showed the anxiolytic effect of TDS using conditioned fear stress-induced freezing behavior in a previous study . Thus, we have shown the excellent anxiolytic effect of TDS using two unique rodent models of anxiety behavior.
Of interest, several studies have indicated that there are relationships between hippocampal neurogenesis and behavioral changes in NSF testing of stress-exposed animals [29, 49]. However, in the present study, chronic treatment with TDS displayed no significant differences in the time to consumption of a food pellet in a NSF test, despite the finding of a significant increase in the number of DCX-positive cells. It will be necessary to carry out further studies to explain why this study failed to find behavioral change in rats chronically administered TDS. Restructuring of the experimental methodology should be considered, including changes in the duration of TDS administration, increasing the sample size of rats chronically administered TDS, and investigation of the effects of TDS in NSF testing that uses models of depressive animals exposed to stressors. In addition, a forced swim test, a novel animal model of depressive disorders, should be done to clarify the effect on the behavioral change of rats undergoing chronic TDS treatment.
In conclusion, this study strongly suggests that 5-HT1A receptor partial agonists are useful and beneficial for the treatment of depressive and anxiety disorders, from the standpoint of hippocampal neurogenesis.
No funding or sponsorship was received for this study or publication of this article. Dr. Yusuke Murata is the guarantor for this article, and takes responsibility for the integrity of the work as a whole.
Conflict of interest
Masayoshi Mori, Yusuke Murata, Asami Matsuo, Tomoyo Takemoto, and Kazunori Mine declare no conflicts of interest.
Compliance with ethics guidelines
All institutional and national guidelines for the care and use of laboratory animals were followed.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.